GT Biopharma, Inc. - רווח למניה בשנים עשר החודשים האחרונים GTBP

GT Biopharma, Inc. (GTBP) bases its future revenues on the development of TriKE drugs for tumor combat. The TTM EPS history visualizes this trajectory, where the -89.72 mark serves as a key metric of the current state. Monopoly access to the cell activation platform ensures high business scalability. Meanwhile, the leukemia therapy market remains open, and demand from centers is currently forming.
פילוחים אנליטיים של חברת GT Biopharma, Inc.

GT Biopharma, Inc. (GTBP) is developing innovative cancer immunotherapy through strategic alliances with global pharma behemoths. The EPS TTM metric reflects the net income allocated per share over the last twelve months. The current EPS TTM level visualizes the monetization efficiency of scientific developments and the TriKE platform. An upward trend confirms revenue scaling, while stagnation signals high trial costs. This metric's dynamics determine the fundamental capital stability of the company.